Therapeutic Asset Ratings

136 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Acp-103 Schizophrenia	Bjorn H. Ebdrup	P3	B (58)
Elpipodect Schizophrenia	Merck Sharp & Dohme LLC	P2	B (58)
BENZTROPINE Schizophrenia	University of Pittsburgh	P4	B (57)
2-Bromo-?-ergocryptine Schizophrenia	VA Pittsburgh Healthcare System	P4	B (56)
Bazedoxifene Schizophrenia	The Alfred	P4	B (56)
DEXKETOPROFEN Schizophrenia	Hôpital le Vinatier	P4	B (56)
il-23 Schizophrenia	University of Maryland, Baltimore	P4	B (56)
METAMIZOLE Schizophrenia	Hôpital le Vinatier	P4	B (56)
NEPENTHE Schizophrenia	Hôpital le Vinatier	P4	B (56)
Nbi-1117568 Schizophrenia	Neurocrine Biosciences	P3	B (56)
Samidorphan Schizophrenia	Alkermes, Inc.	P3	B (56)
Inomax Schizophrenia	Beth Israel Deaconess Medical Center	P2	CCC (55)
Infliximab Schizophrenia	Emory University	P4	CCC (54)
Buspirone Schizophrenia	Chuanfu Song	P3	CCC (54)
Paroxetine Schizophrenia	Dr. Inge Winter	P3	CCC (54)
Inidascamine Schizophrenia	Recognify Life Sciences	P2	CCC (54)
Lipitor Schizophrenia	Central South University	P3	CCC (52)
Tiagabine Schizophrenia	Beth Israel Deaconess Medical Center	P3	CCC (52)
VENLOR Schizophrenia	Dr. Inge Winter	P3	CCC (52)
ly03020 Schizophrenia	Luye Pharma Group Ltd.	P2	CCC (52)
MOXIFLOXACIN Schizophrenia	Merck Sharp & Dohme LLC	P1	CCC (52)
Benzoic Acid Schizophrenia	National Cheng-Kung University Hospital	P2	CCC (51)
Luvadaxistat Schizophrenia	Neurocrine Biosciences	P2	CCC (51)
jx11502ma Schizophrenia	Zhejiang Jingxin Pharmaceutical Co., Ltd.	P1/2	CCC (49)
BROMAZEPAM Schizophrenia	Rakitzi, Stavroula	P3	CCC (48)

Showing 51 to 75 of 136 assets